Table 1 Demographic and clinical-pathologic characteristics of study cohorts
From: A multiplex immunoassay for the non-invasive detection of bladder cancer
Cohort #1 | P value* | Cohort #2 | P value* | |||
|---|---|---|---|---|---|---|
Bladder cancera (n = 29) | Benignb and healthy controls (n = 33) | Bladder cancera (n = 100) | Benignb and healthy controls (n = 100) | |||
Median age (range, years) | 68 (51, 93) | 50 (20, 81) | <0.0001 | 70 (20, 89) | 50.5 (18, 81) | <0.0001 |
Male:female ratio | 25:4 | 27:6 | 0.639 | 81:18 | 81:19 | 0.882 |
Clinical stage and grade | ||||||
Tis high-grade | 3 (10.3 %) | 4 (4.0 %) | ||||
Ta low-grade | 4 (13.8 %) | 17 (17.0 %) | ||||
Ta high-grade | 6 (20.7 %) | 11 (11.0 %) | ||||
T1 low-grade | 0 (0 %) | 4 (4.0 %) | ||||
T1 high-grade | 3 (10.3 %) | 22 (22.0 %) | ||||
≥T2 high-grade | 13 (44.8 %) | 42 (42.0 %) | ||||